Search Results

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: nano-PROTAC (A nano-particle containing a Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety, which is activatable in the presence of a specific stimulus; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: LYTAC (Lysosome Targeting Chimera; structured as glycopeptide ligand--linker--target binding moiety; target degraded via endosome-lysosome system) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: SNIPER (Specific and Non-genetic Inhibitor-of-apoptosis proteins (IAPs)-dependent Protein Eraser; structured as IAP ligand--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies ...

METHOD: SNIPER (Specific and Non-genetic Inhibitor-of-apoptosis proteins (IAPs)-dependent Protein Eraser; structured as IAP ligand--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies ...

METHOD: SNIPER (Specific and Non-genetic Inhibitor-of-apoptosis proteins (IAPs)-dependent Protein Eraser; structured as IAP ligand--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies ...

METHOD: SNIPER (Specific and Non-genetic Inhibitor-of-apoptosis proteins (IAPs)-dependent Protein Eraser; structured as IAP ligand--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies ...

METHOD: SNIPER (Specific and Non-genetic Inhibitor-of-apoptosis proteins (IAPs)-dependent Protein Eraser; structured as IAP ligand--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: HaloPROTAC (PROTAC variant that induces degradation of HaloTag fusion proteins; structured as E3 binding moiety--linker--HaloTag binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein ...

METHOD: HaloPROTAC (PROTAC variant that induces degradation of HaloTag fusion proteins; structured as E3 binding moiety--linker--HaloTag binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein ...

METHOD: HaloPROTAC (PROTAC variant that induces degradation of HaloTag fusion proteins; structured as E3 binding moiety--linker--HaloTag binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: HaloPROTAC (PROTAC variant that induces degradation of HaloTag fusion proteins; structured as E3 binding moiety--linker--HaloTag binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: HaloPROTAC (PROTAC variant that induces degradation of HaloTag fusion proteins; structured as E3 binding moiety--linker--HaloTag binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: CLIPTAC (PROTAC variant formed in cells by click chemistry; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. ...

METHOD: CLIPTAC (PROTAC variant formed in cells by click chemistry; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: Opto-PROTAC (PROTAC variant in which degradation activity can be regulated by exposure to light; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other ...

METHOD: Opto-PROTAC (PROTAC variant in which degradation activity can be regulated by exposure to light; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other ...

METHOD: LYTAC (Lysosome Targeting Chimera; structured as glycopeptide ligand--linker--target binding moiety; target degraded via endosome-lysosome system) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: LYTAC (Lysosome Targeting Chimera; structured as glycopeptide ligand--linker--target binding moiety; target degraded via endosome-lysosome system) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: HaloPROTAC (PROTAC variant that induces degradation of HaloTag fusion proteins; structured as E3 binding moiety--linker--HaloTag binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein ...

METHOD: HaloPROTAC (PROTAC variant that induces degradation of HaloTag fusion proteins; structured as E3 binding moiety--linker--HaloTag binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: AUTAC/ATTEC (Autophagosome Tethering Compound; structured as a LC3 binding moiety--linker--target binding moiety; target degraded via autophagic degradation) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: SNIPER (Specific and Non-genetic Inhibitor-of-apoptosis proteins (IAPs)-dependent Protein Eraser; structured as IAP ligand--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: Opto-PROTAC (PROTAC variant in which degradation activity can be regulated by exposure to light; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other ...

METHOD: Opto-PROTAC (PROTAC variant in which degradation activity can be regulated by exposure to light; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other ...

METHOD: Opto-PROTAC (PROTAC variant in which degradation activity can be regulated by exposure to light; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other ...

METHOD: Opto-PROTAC (PROTAC variant in which degradation activity can be regulated by exposure to light; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: SNIPER (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase; NOTE: the format for this BVL name is (E3:GFP binding scaffold fusion --- Target:GFP fusion)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase; NOTE: the format for this BVL name is (E3:GFP binding scaffold fusion --- Target:GFP fusion)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase; NOTE: the format for this BVL name is (E3:GFP binding scaffold fusion --- Target:GFP fusion)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase; NOTE: the format for this BVL name is (E3:GFP binding scaffold fusion --- Target:GFP fusion)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase; NOTE: the format for this BVL name is (E3:GFP binding scaffold fusion --- Target:GFP fusion)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase; NOTE: the format for this BVL name is (E3:GFP binding scaffold fusion --- Target:GFP fusion)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase; NOTE: the format for this BVL name is (E3:GFP binding scaffold fusion --- Target:GFP fusion)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase; NOTE: the format for this BVL name is (E3:GFP binding scaffold fusion --- Target:GFP fusion)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase; NOTE: the format for this BVL name is (E3:GFP binding scaffold fusion --- Target:GFP fusion)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase; NOTE: the format for this BVL name is (E3:GFP binding scaffold fusion --- Target:GFP fusion)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase; NOTE: the format for this BVL name is (E3:GFP binding scaffold fusion --- Target:GFP fusion)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase; NOTE: the format for this BVL name is (E3:GFP binding scaffold fusion --- Target:GFP fusion)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: AUTAC/ATTEC (Autophagosome Tethering Compound; structured as a LC3 autophagosome recruiting moiety--linker--target binding moiety; target degraded via autophagic degradation) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to ...

METHOD: AUTAC/ATTEC (Autophagosome Tethering Compound; structured as a LC3 autophagosome recruiting moiety--linker--target binding moiety; target degraded via autophagic degradation) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to ...

METHOD: AUTAC/ATTEC (Autophagosome Tethering Compound; structured as a LC3 autophagosome recruiting moiety--linker--target binding moiety; target degraded via autophagic degradation) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: AbTAC (Antibody-based PROTACs, in which bispecific IgGs bind to two proteins simultaneously, an E3 and POI; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. ...

METHOD: AbTAC (Antibody-based PROTACs, in which bispecific IgGs bind to two proteins simultaneously, an E3 and POI; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. ...

METHOD: AbTAC (Antibody-based PROTACs, in which bispecific IgGs bind to two proteins simultaneously, an E3 and POI; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. ...

METHOD: AbTAC (Antibody-based PROTACs, in which bispecific IgGs bind to two proteins simultaneously, an E3 and POI; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. ...

METHOD: AbTAC (Antibody-based PROTACs, in which bispecific IgGs bind to two proteins simultaneously, an E3 and POI; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. ...

METHOD: AbTAC (Antibody-based PROTACs, in which bispecific IgGs bind to two proteins simultaneously, an E3 and POI; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. ...

METHOD: AbTAC (Antibody-based PROTACs, in which bispecific IgGs bind to two proteins simultaneously, an E3 and POI; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. ...

METHOD: AbTAC (Antibody-based PROTACs, in which bispecific IgGs bind to two proteins simultaneously, an E3 and POI; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. ...

METHOD: AbTAC (Antibody-based PROTACs, in which bispecific IgGs bind to two proteins simultaneously, an E3 and POI; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. ...

METHOD: AbTAC (Antibody-based PROTACs, in which bispecific IgGs bind to two proteins simultaneously, an E3 and POI; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: DUBTAC (Deubiquitinase-targeting chimera; structured as DUB binding moiety--linker--target binding moiety; target deubiquitinated via recruited deubiquitinase (DUB)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: DUBTAC (Deubiquitinase-targeting chimera; structured as DUB binding moiety--linker--target binding moiety; target deubiquitinated via recruited deubiquitinase (DUB)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: DUBTAC (Deubiquitinase-targeting chimera; structured as DUB binding moiety--linker--target binding moiety; target deubiquitinated via recruited deubiquitinase (DUB)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: DUBTAC (Deubiquitinase-targeting chimera; structured as DUB binding moiety--linker--target binding moiety; target deubiquitinated via recruited deubiquitinase (DUB)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: DUBTAC (Deubiquitinase-targeting chimera; structured as DUB binding moiety--linker--target binding moiety; target deubiquitinated via recruited deubiquitinase (DUB)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: DUBTAC (Deubiquitinase-targeting chimera; structured as DUB binding moiety--linker--target binding moiety; target deubiquitinated via recruited deubiquitinase (DUB)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: DUBTAC (Deubiquitinase-targeting chimera; structured as DUB binding moiety--linker--target binding moiety; target deubiquitinated via recruited deubiquitinase (DUB)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: Molecular Glue (Single chemical moiety that contacts both the E3 and the target in a ternary complex; structured as a single chemical entity without linkers; target degraded via UPS or otherwise inactivated in the ternary complex) | Bivalent ligands are compounds that bridge two protein partners to form a ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: RIBOTAC (Ribonuclease Targeting Chimera; structured as a ribonuclease recruiting moiety-linker-RNA binding moiety) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other heterobifunctional compounds in ...

METHOD: RIBOTAC (Ribonuclease Targeting Chimera; structured as a ribonuclease recruiting moiety-linker-RNA binding moiety) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other heterobifunctional compounds in ...

METHOD: RIBOTAC (Ribonuclease Targeting Chimera; structured as a ribonuclease recruiting moiety-linker-RNA binding moiety) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other heterobifunctional compounds in ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase; NOTE: the format for this BVL name is (E3:GFP binding scaffold fusion --- Target:GFP fusion)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: bioPROTAC (Engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase; NOTE: the format for this BVL name is (E3:GFP binding scaffold fusion --- Target:GFP fusion)) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...

METHOD: PROTAC (Proteolysis Targeting Chimera; structured as E3 binding moiety--linker--target binding moiety; target degraded via UPS) | Bivalent ligands are compounds that bridge two protein partners to form a ternary complex, resulting in ubiquitin-proteasome mediated degradation, lysosomal degradation or other means of target protein inactivation. Applies to PROTACs and other ...